Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Ildong Holdings is a South Korean pharmaceutical conglomerate operating through subsidiaries in generic and specialty drug manufacturing, with primary exposure to domestic Korean healthcare markets. The company faces significant operational headwinds evidenced by -10.1% revenue decline and -68.5% net income contraction, while maintaining a low-margin business model (3.4% net margin) typical of generic drug manufacturers. Recent stock volatility (+78.4% 1-year, -18.9% 3-month) suggests speculative trading rather than fundamental improvement.
Generates revenue through high-volume, low-margin generic drug sales to Korean hospitals, pharmacies, and government healthcare programs. Pricing power is limited due to government reimbursement controls and intense domestic competition from local manufacturers and multinational generics. The 0.0% reported gross margin (likely data anomaly) and 2.5% operating margin indicate extreme cost pressures typical of commoditized generic manufacturers. Value capture depends on manufacturing efficiency, regulatory approval speed, and distribution network density rather than product differentiation.
Korean National Health Insurance reimbursement rate changes and government drug pricing policies
Generic drug approval pipeline progress and biosimilar development milestones
Raw material cost inflation for active pharmaceutical ingredients (APIs), particularly from Chinese suppliers
Domestic pharmaceutical market consolidation and M&A activity among Korean drugmakers
Won/USD exchange rate movements affecting imported API costs and export competitiveness
Korean government healthcare reform initiatives targeting pharmaceutical cost reduction through mandatory price cuts and increased generic substitution mandates
Biosimilar competition eroding margins on legacy specialty products as patents expire and manufacturing technology commoditizes
Chinese API supplier consolidation and export restrictions creating supply chain vulnerabilities and raw material cost inflation
Multinational generic manufacturers (Teva, Mylan/Viatris, Sandoz) expanding Korean market presence with superior scale economics
Domestic consolidation among Korean pharmaceutical companies creating larger, better-capitalized competitors
Limited R&D investment capacity (evidenced by low margins and high capex burden) restricting ability to develop differentiated specialty products
Liquidity crisis risk with 0.75x current ratio indicating insufficient short-term assets to cover liabilities, particularly concerning given -68.5% net income decline
Debt refinancing risk on 1.84x debt/equity with only $1.7B free cash flow generation against likely substantial near-term maturities
Negative working capital dynamics suggested by current ratio below 1.0x, indicating potential supplier payment delays or inventory liquidation pressure
low - Pharmaceutical demand is relatively inelastic to GDP fluctuations as healthcare spending remains stable through economic cycles. However, government budget constraints during recessions can pressure reimbursement rates. The -10.1% revenue decline appears company-specific rather than cyclical, suggesting operational or competitive issues.
Rising interest rates create dual pressure: (1) increased debt service costs on 1.84x debt/equity ratio, particularly problematic given weak 0.75x current ratio and limited liquidity buffer, and (2) higher discount rates compress valuation multiples for low-growth, low-margin businesses. Current 4.7x EV/EBITDA suggests market already pricing in elevated refinancing risk. Korean won interest rate policy (Bank of Korea base rate) more relevant than US Fed Funds for domestic operations.
High credit exposure given weak liquidity position (0.75x current ratio), elevated leverage (1.84x D/E), and deteriorating cash generation (-68.5% net income decline). The company requires access to Korean corporate credit markets for working capital and refinancing. Tightening credit conditions or credit rating downgrades would significantly increase financing costs and restrict operational flexibility.
value/distressed - The 0.2x price/sales and 0.7x price/book valuations suggest deep value investors or distressed/special situations funds betting on operational turnaround or asset liquidation value. The extreme volatility (78.4% 1-year gain followed by -18.9% 3-month decline) indicates speculative retail participation rather than institutional quality investors. Low 1.3% FCF yield and deteriorating fundamentals make this unsuitable for income or quality-focused investors.
high - Recent performance shows extreme volatility with 78.4% annual gain reversing to -18.9% quarterly decline, suggesting low liquidity, speculative positioning, and high sensitivity to company-specific news flow. The combination of operational distress, balance sheet concerns, and low institutional ownership typically produces beta >1.5x and frequent gap moves on earnings announcements.